Literature DB >> 2433342

Probing functional sites on complement protein B with monoclonal antibodies. Evidence for C3b-binding sites on Ba.

A Ueda, J F Kearney, K H Roux, J E Volanakis.   

Abstract

We used four mouse monoclonal antibodies (Mab) as probes of functional sites of human complement protein B. Two Mab, HA4-1B (gamma 2a kappa) and HA4-15 (gamma 2a kappa), reacted with the same or adjacent epitopes on the Bb fragment of B, while the other two, HA4-1A (gamma 1 kappa) and FD3-20 (gamma 1 kappa), reacted with distinct epitopes on Ba. All reactive epitopes were expressed on native B and only one, recognized by the anti-Ba Mab HA4-1A was more reactive on isolated Ba than on B. These binding specificities were determined by direct binding radioassays and confirmed by inhibition studies. Immunoelectron microscopy of B and Bb in complex with anti-Ba and anti-Bb revealed that the recognized epitopes are on opposite sides of the molecule and are on discrete domains. All four Mab inhibited the hemolytic activity of B, although with different efficiencies and through different mechanisms. The main effect of the two anti-Bb Mab was an increased rate of loss of hemolytic sites from preformed EC3bBb C3 convertase presumably through accelerated dissociation of Bb. On the other hand, the main effect of the two anti-Ba Mab was inhibition of binding of B to C3b. HA4-1A was more efficient, inhibiting by 50% the binding of [125I]B to EC3b at 10 micrograms/ml as IgG and at 13 micrograms/ml as Fab. The data suggest that a binding site for C3b on intact B is located on the Ba portion of the molecule.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2433342

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  New structural motifs on the chymotrypsin fold and their potential roles in complement factor B.

Authors:  H Jing; Y Xu; M Carson; D Moore; K J Macon; J E Volanakis; S V Narayana
Journal:  EMBO J       Date:  2000-01-17       Impact factor: 11.598

2.  Complement regulation at the molecular level: the structure of decay-accelerating factor.

Authors:  P Lukacik; P Roversi; J White; D Esser; G P Smith; J Billington; P A Williams; P M Rudd; M R Wormald; D J Harvey; M D M Crispin; C M Radcliffe; R A Dwek; D J Evans; B P Morgan; R A G Smith; S M Lea
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-20       Impact factor: 11.205

3.  The structure of C2b, a fragment of complement component C2 produced during C3 convertase formation.

Authors:  Vengadesan Krishnan; Yuanyuan Xu; Kevin Macon; John E Volanakis; Sthanam V L Narayana
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-02-20

4.  Complement activation in factor D-deficient mice.

Authors:  Y Xu; M Ma; G C Ippolito; H W Schroeder; M C Carroll; J E Volanakis
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

5.  Molecular characterization of human complement factor B subtypes.

Authors:  C Davrinche; M Abbal; A Clerc
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

6.  The principal site of glycation of human complement factor B.

Authors:  M A Niemann; A S Bhown; E J Miller
Journal:  Biochem J       Date:  1991-03-01       Impact factor: 3.857

7.  Murine monoclonal anti-Ba antibody that enhances haemolytic activity of factor B.

Authors:  E Tanaka; K Hong; T Kinoshita; Y Takata; H Kozono; J Takeda; A Yoden; K Inoue
Journal:  Immunology       Date:  1991-08       Impact factor: 7.397

8.  Production and functional activity of a recombinant von Willebrand factor-A domain from human complement factor B.

Authors:  S C Williams; J Hinshelwood; S J Perkins; R B Sim
Journal:  Biochem J       Date:  1999-09-15       Impact factor: 3.857

9.  The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).

Authors:  Fredrik Bexborn; Per Ola Andersson; Hui Chen; Bo Nilsson; Kristina N Ekdahl
Journal:  Mol Immunol       Date:  2007-12-21       Impact factor: 4.407

10.  Complement activation by whole endotoxin is blocked by a monoclonal antibody to factor B.

Authors:  C W Clardy
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.